DoP promotes RnD in Pharma Medtech Sector with AI Integration
New Delhi: The Department of Pharmaceuticals (DoP) has taken steps to promote research and development (R&D) in the sector, including in the areas of artificial intelligence (AI) and machine learning, in the pharmaceutical sector through the Scheme for Promotion of Research and Innovation in the Pharma Medtech sector.
This was said by the Union Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel in Rajya Sabha in written reply to a question.
Further, the National Institutes of Pharmaceutical Education and Research (NIPER) under the aegis of DoP have introduced topics related to AI and block chain technology in their courses and they provide training to students in AI-based tools to build human resource capacities in these areas for the pharmaceutical sector.
In addition, the Department of Biotechnology also supports AI-based research activities in the biotech sector, particularly in the healthcare and agriculture areas, in order to leverage emerging technologies for these sectors.
Further, the Pharmaceuticals and Medical Devices Bureau of India under the Department of Pharmaceuticals, with the assistance of the Centre for Development of Advanced Computing, has undertaken a pilot project to evaluate the feasibility of a block-chain-based track-and-trace system for Pradhan Mantri Bhartiya Janaushadhi Pariyojana.
The Department of Pharmaceuticals, Government of India, has recently hosted an Industry Dialogue on the scheme for Promotion of Research and Innovation in the Pharma-MedTech Sector (PRIP) at Bangalore on 25th March 2025. The event served as a significant platform for representatives from industry, startups, and research institutes, including representatives from the Indian Council for Medical Research (ICMR), Council of Scientific and Industrial Research (CSIR), and innovation hubs like C-CAMP (Centre for Cellular and Molecular Platforms), to engage in discussions aimed at fostering collaboration, and leveraging government initiatives to accelerate research and development (R&D) in the pharmaceutical and MedTech sectors.
